Efficacy and Safety of Tralokinumab with Concomitant Topical Corticosteroids in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of the ECZTRA 3 Trial

Efficacy And Safety ◽

Abstract not available.

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

JAMA Dermatology ◽

10.1001/jamadermatol.2020.3260 ◽

2020 ◽

Vol 156 (12) ◽

pp. 1333 ◽

Cited By ~ 2

Author(s):

Kristian Reich ◽

Kenji Kabashima ◽

Ketty Peris ◽

Jonathan I. Silverberg ◽

Lawrence F. Eichenfield ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Faculty Opinions recommendation of Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534767.793543516 ◽

2018 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Phase Ii ◽

Phase Ii Trial ◽

Efficacy And Safety ◽

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.054 ◽

2020 ◽

Vol 83 (5) ◽

pp. 1282-1293 ◽

Cited By ~ 10

Author(s):

Amy S. Paller ◽

Elaine C. Siegfried ◽

Diamant Thaçi ◽

Andreas Wollenberg ◽

Michael J. Cork ◽

...

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety ◽

Phase 3 ◽

Topical Corticosteroids ◽

Double Blinded

Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.102 ◽

2020 ◽

Vol 4 (6) ◽

pp. s102

Author(s):

Stephan Weidinger ◽

Jonathan Silverberg ◽

Darryl Toth ◽

Thomas Bieber ◽

Andrew Alexis ◽

...

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Abstract not available.

28186 Efficacy and safety of tralokinumab monotherapy in North American adult patients with moderate-to-severe atopic dermatitis: A subanalysis of the ECZTRA 2 trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2021.06.726 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB178

Author(s):

Marni Wiseman ◽

April W. Armstrong ◽

Jennifer Soung ◽

Lorne Albrecht ◽

Mark Lomaga ◽

...

Keyword(s):

Atopic Dermatitis ◽

North American ◽

Adult Patients ◽

Efficacy And Safety ◽

American Adult

Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.60 ◽

2021 ◽

Vol 5 (6) ◽

pp. s60

Author(s):

Jan Gutermuth ◽

Andrew Pink ◽

Margitta Worm ◽

Lise Soldbro ◽

Thomas Mark ◽

...

Keyword(s):

Atopic Dermatitis ◽

Subgroup Analysis ◽

Prior History ◽

Efficacy And Safety ◽

Topical Corticosteroids ◽

History Of ◽

Post Hoc

N/A

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.01.017 ◽

2018 ◽

Vol 78 (5) ◽

pp. 863-871.e11 ◽

Cited By ~ 123

Author(s):

Eric L. Simpson ◽

Carsten Flohr ◽

Lawrence F. Eichenfield ◽

Thomas Bieber ◽

Howard Sofen ◽

...

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Phase Ii ◽

Phase Ii Trial ◽

Efficacy And Safety ◽

Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis

Case Medical Research ◽

10.31525/ct1-nct04178967 ◽

2019 ◽

Author(s):

Keyword(s):

Atopic Dermatitis ◽

Efficacy And Safety

Faculty Opinions recommendation of Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534768.793555539 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind

Faculty Opinions recommendation of Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534768.793545728 ◽

2018 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind